Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Essler

Showing results (141-150 of 208) with videos related to

Pageof 21
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|August 8, 2025
Probabilistic Mapping of Magnetic Resonance-Guided Focused Ultrasound (MRgFUS) Thalamotomy Targets in Essential Tremor and Tremor-Dominant Parkinson's Disease: Insights from a German CohortJonas Krauss, Neeraj Upadhyay, Veronika Purrer, et al.
Theranostics|November 22, 2017
Clinical Translation and First In-Human Use of [<sup>44</sup>Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate CancerElisabeth Eppard, Ana de la Fuente, Martina Benešová, et al.
Cell Reports|October 11, 2018
A RECK-WNT7 Receptor-Ligand Interaction Enables Isoform-Specific Regulation of Wnt BioavailabilityMario Vallon, Kanako Yuki, Thi D Nguyen, et al.
Journal of Clinical Medicine|December 11, 2022
Multidisciplinary Postoperative Validation of <sup>18</sup>F-FDG PET/CT Scan in Nodal Staging of Resected Non-Small Cell Lung CancerBenedetta Bedetti, Philipp Schnorr, Sarah May, et al.
Journal of Cancer Research and Clinical Oncology|February 4, 2024
Expression of the microtubule-associated protein 2 (MAP2) as a potential independent prognostic marker in prostate cancerJohannes Stein, Eliana Krappe, Anika Kremer, et al.
Pharmaceuticals (Basel, Switzerland)|January 21, 2022
Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and TherapyCristina Barca, Christoph M Griessinger, Andreas Faust, et al.
Current Medicinal Chemistry|October 14, 2024
FOXN3-AS1: A Candidate Prognostic Marker and Epigenetic Target with Immunotherapeutic Implications in Acute Myeloid LeukemiaFangfang Ge, Yulu Wang, Peng Chen, et al.
Neuroimage|April 12, 2026
Long-term alterations of cerebellar structure after premature birthMarcel Daamen, Lukas Scheef, Aurore Menegaux, et al.
Clinical Nuclear Medicine|April 19, 2022
Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor-Directed Molecular Imaging and TherapySebastian E Serfling, Philipp E Hartrampf, Yingjun Zhi, et al.
Nuklearmedizin. Nuclear Medicine|July 13, 2021
Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumoursBarbara Kreppel, Maria Angeles Gonzalez-Carmona, Georg Feldmann, et al.
Pageof 21

Showing results (141-150 of 208) with videos related to

Sort By:
Pageof 21
Movement Disorders : Official Journal of the Movement Disorder Society|August 8, 2025
Probabilistic Mapping of Magnetic Resonance-Guided Focused Ultrasound (MRgFUS) Thalamotomy Targets in Essential Tremor and Tremor-Dominant Parkinson's Disease: Insights from a German CohortJonas Krauss, Neeraj Upadhyay, Veronika Purrer, et al.
Theranostics|November 22, 2017
Clinical Translation and First In-Human Use of [<sup>44</sup>Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate CancerElisabeth Eppard, Ana de la Fuente, Martina Benešová, et al.
Cell Reports|October 11, 2018
A RECK-WNT7 Receptor-Ligand Interaction Enables Isoform-Specific Regulation of Wnt BioavailabilityMario Vallon, Kanako Yuki, Thi D Nguyen, et al.
Journal of Clinical Medicine|December 11, 2022
Multidisciplinary Postoperative Validation of <sup>18</sup>F-FDG PET/CT Scan in Nodal Staging of Resected Non-Small Cell Lung CancerBenedetta Bedetti, Philipp Schnorr, Sarah May, et al.
Journal of Cancer Research and Clinical Oncology|February 4, 2024
Expression of the microtubule-associated protein 2 (MAP2) as a potential independent prognostic marker in prostate cancerJohannes Stein, Eliana Krappe, Anika Kremer, et al.
Pharmaceuticals (Basel, Switzerland)|January 21, 2022
Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and TherapyCristina Barca, Christoph M Griessinger, Andreas Faust, et al.
Current Medicinal Chemistry|October 14, 2024
FOXN3-AS1: A Candidate Prognostic Marker and Epigenetic Target with Immunotherapeutic Implications in Acute Myeloid LeukemiaFangfang Ge, Yulu Wang, Peng Chen, et al.
Neuroimage|April 12, 2026
Long-term alterations of cerebellar structure after premature birthMarcel Daamen, Lukas Scheef, Aurore Menegaux, et al.
Clinical Nuclear Medicine|April 19, 2022
Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor-Directed Molecular Imaging and TherapySebastian E Serfling, Philipp E Hartrampf, Yingjun Zhi, et al.
Nuklearmedizin. Nuclear Medicine|July 13, 2021
Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumoursBarbara Kreppel, Maria Angeles Gonzalez-Carmona, Georg Feldmann, et al.
Pageof 21